tirzepatide fda approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly BioCentury - Nov. 8 Quick

Substances may be used to manage anxiety, suppress appetite, regulate mood, or cope with distress related to eating disorder symptoms

Patient-reported adherence and difficulties experienced with the dosing requirements were assessed after oral semaglutide was initiated

In the pivotal Phase 3 trials that led to FDA approval, participants receiving Tesamorelin experienced a 15.2% reduction in visceral adipose tissue compared to a 5% increase in the placebo group after 26 weeks

Is the Benefit Only From Weight Loss

Want to understand your metabolic and hormonal health before committing to any treatment

Positive Experiences Many customers highlight relief from bloating and improved digestion within the first few weeks of use